Review



sequenom massarray methylation  (Sequenom)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Sequenom sequenom massarray methylation
    Fig. 4. Cd interfered with the DNA <t>methylation</t> of Oct4 and Nanog of mouse ES cells into ovarian GCs. A and E represented the methylation status of CpG islands on DNA templates in the promoter regions of both factors was evaluated using the Sequenom <t>MassARRAY</t> Methylation. B and F: DNA methylation rate of CpG locus in the promoter region of different sites of both factors. C–K represented the degree of DNA methylation on different fragments of the factors in maps and DNA methylation rate in the promoter region in each fragment and groups. Data are presented as the mean ± SD, *P < 0.05 compared with the IA group.
    Sequenom Massarray Methylation, supplied by Sequenom, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/pm34871855-191-17-17?v=Sequenom
    Average 86 stars, based on 1 article reviews
    sequenom massarray methylation - by Bioz Stars, 2026-08
    86/100 stars

    Images

    1) Product Images from "Ultra-high field spinal cord MRI in multiple sclerosis: Where are we standing? A literature review."

    Article Title: Ultra-high field spinal cord MRI in multiple sclerosis: Where are we standing? A literature review.

    Journal: Multiple sclerosis and related disorders

    doi: 10.1016/j.msard.2021.103436

    Fig. 4. Cd interfered with the DNA methylation of Oct4 and Nanog of mouse ES cells into ovarian GCs. A and E represented the methylation status of CpG islands on DNA templates in the promoter regions of both factors was evaluated using the Sequenom MassARRAY Methylation. B and F: DNA methylation rate of CpG locus in the promoter region of different sites of both factors. C–K represented the degree of DNA methylation on different fragments of the factors in maps and DNA methylation rate in the promoter region in each fragment and groups. Data are presented as the mean ± SD, *P < 0.05 compared with the IA group.
    Figure Legend Snippet: Fig. 4. Cd interfered with the DNA methylation of Oct4 and Nanog of mouse ES cells into ovarian GCs. A and E represented the methylation status of CpG islands on DNA templates in the promoter regions of both factors was evaluated using the Sequenom MassARRAY Methylation. B and F: DNA methylation rate of CpG locus in the promoter region of different sites of both factors. C–K represented the degree of DNA methylation on different fragments of the factors in maps and DNA methylation rate in the promoter region in each fragment and groups. Data are presented as the mean ± SD, *P < 0.05 compared with the IA group.

    Techniques Used: DNA Methylation Assay, Methylation

    Fig. 5. Cd interfered with the DNA methylation of Amhr2 and Sox2 of mouse ES cells into ovarian GCs. A and E represented the methylation status of CpG islands on DNA templates in the promoter regions of both factors was evaluated using the Sequenom MassARRAY Methylation. B and F: DNA methylation rate of CpG locus in the promoter region of different sites of both factors. C-K represented the degree of DNA methylation on different fragments of the factors in maps and DNA methylation rate in the promoter region in each fragment and groups. Data are presented as the mean ± SD, *P < 0.05 compared with the IA group.
    Figure Legend Snippet: Fig. 5. Cd interfered with the DNA methylation of Amhr2 and Sox2 of mouse ES cells into ovarian GCs. A and E represented the methylation status of CpG islands on DNA templates in the promoter regions of both factors was evaluated using the Sequenom MassARRAY Methylation. B and F: DNA methylation rate of CpG locus in the promoter region of different sites of both factors. C-K represented the degree of DNA methylation on different fragments of the factors in maps and DNA methylation rate in the promoter region in each fragment and groups. Data are presented as the mean ± SD, *P < 0.05 compared with the IA group.

    Techniques Used: DNA Methylation Assay, Methylation



    Similar Products

    massarray sequenom detection  (Sequenom)
    90
    Sequenom massarray sequenom detection
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Massarray Sequenom Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/pmc09085879-184-7-8?v=Sequenom
    Average 90 stars, based on 1 article reviews
    massarray sequenom detection - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    snps detected by sequenom massarray rs1000 platform  (Sequenom)
    90
    Sequenom snps detected by sequenom massarray rs1000 platform
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Snps Detected By Sequenom Massarray Rs1000 Platform, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/pm33127268-102-12-16?v=Sequenom
    Average 90 stars, based on 1 article reviews
    snps detected by sequenom massarray rs1000 platform - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    mass spectrometry-based detection (sequenom massarray platform)  (Sequenom)
    90
    Sequenom mass spectrometry-based detection (sequenom massarray platform)
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Mass Spectrometry Based Detection (Sequenom Massarray Platform), supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/pmc06107190-119-25-28?v=Sequenom
    Average 90 stars, based on 1 article reviews
    mass spectrometry-based detection (sequenom massarray platform) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    detection limitation of sequenom massarray  (Sequenom)
    90
    Sequenom detection limitation of sequenom massarray
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Detection Limitation Of Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/pmc05863829-107-32-31?v=Sequenom
    Average 90 stars, based on 1 article reviews
    detection limitation of sequenom massarray - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    mass spectrometric detection (sequenom massarray)  (Sequenom)
    90
    Sequenom mass spectrometric detection (sequenom massarray)
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Mass Spectrometric Detection (Sequenom Massarray), supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/pm26003169-313-9-12?v=Sequenom
    Average 90 stars, based on 1 article reviews
    mass spectrometric detection (sequenom massarray) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    mass spectrometric detection sequenom massarray  (Sequenom)
    90
    Sequenom mass spectrometric detection sequenom massarray
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Mass Spectrometric Detection Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/pmc04258414-60-7-10?v=Sequenom
    Average 90 stars, based on 1 article reviews
    mass spectrometric detection sequenom massarray - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system  (Sequenom)
    90
    Sequenom single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Single Nucleotide Extension Reaction With Allele Detection By Mass Spectrometry Sequenom Massarray System, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/pmc06869631-79-12-14?v=Sequenom
    Average 90 stars, based on 1 article reviews
    single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

    Journal: Cell Death & Disease

    Article Title: DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334

    doi: 10.1038/s41419-022-04895-6

    Figure Lengend Snippet: A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

    Article Snippet: And meanwhile, in clinical samples, we used MassArray Sequenom detection to further verify the DNA methylation changes of ZNF334 promoter in cancerous tissues and adjacent tissues.

    Techniques: Methylation, Expressing, Western Blot, Mass Spectrometry, Sequencing